The Abu Dhabi Investment Authority (Adia) will invest USD 200 mn in Indian medical device manufacturer Micro Life Sciences (also known as Meril) through a subsidiary, acquiring a 3% stake in the firm, according to a press release (pdf). The investment values Meril at USD 6.6 bn. The agreement is subject to regulatory approval from the Competition Commission of India.

We knew this was coming: Adia was reportedly in late-stage discussions to invest in Meril as the company gears up for an IPO. Meril’s fundraising round was expected to total USD 250-300 mn, with multiple investors anticipated to participate, including Singapore’s Temasek Holdings. The IPO is likely within 12 to 18 months.

About the company: Founded by Bilakhia Group, Meril focuses on advanced solutions across cardiovascular, structural heart, orthopaedics, endo-surgery, in-vitro diagnostics, and surgical robotics.

REMEMBER- Adia has been actively expanding its India portfolio in 2025. The sovereign wealth fund invested 41.3 crore (c. AED 17.7 mn) in the USD 395 mn (AED 1.5 bn) IPO of Indian drugmaker Anthem Biosciences. It also deployed around USD 310 mn (AED 1.1 bn) for a 5.1% stake in IDFC First Bank, and participated in HDB Financial Services’ 3.4k crore (c. AED 1.5 bn) pre-IPO funding round.

Tags: